AACR 2024 Presentations
AACR ANNUAL MEETING 2024
April 5-10, 2024
San Diego Convention Center, San Diego, CA
April 7, 2024, 3:40 PM – 3:55 PM | Session MS.IM01.03 – Tumor-Targeted Immune Cell Engagers
Hart, K. C., et al. IGM-2644, a CD38xCD3 bispecific IgM T cell engager, shows enhanced anti-tumor activity compared to daratumumab in preclinical models of multiple myeloma. In: Proceedings of the 115th Annual Meeting of the American Association for Cancer Research; 2024 April 5-10; San Diego, CA. Philadelphia (PA): AACR; 2024.
April 8, 2024, 9:00 AM – 12:30 PM | Session PO.ET01.02 – Antibody-Drug Conjugates and Bispectific Antibodies
Desbois, M. et al. Novel combinations of aplitabart, a DR5 agonist IgM antibody, with ADCs or chemotherapeutic agents lead to robust anti-tumor responses in solid tumor models. In: Proceedings of the 115th Annual Meeting of the American Association for Cancer Research; 2024 April 5-10; San Diego, CA. Philadelphia (PA): AACR; 2024.
April 10, 2024, 9:00 AM – 12:30 PM | Session PO.IM01.18 – Targeted Immune Cell Engagers
Xue, J. et al. Costimulatory IgM T-cell engagers with enhanced and durable cytotoxicity. In: Proceedings of the 115th Annual Meeting of the American Association for Cancer Research; 2024 April 5-10; San Diego, CA. Philadelphia (PA): AACR; 2024.